3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Breast Neoplasms
2
Vaping
1
Tobacco Use Disorder
1
Stomach Neoplasms
1
Ovarian Neoplasms
1
Multiple Myeloma
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
1
Granulosa Cell Tumor
1
Endometrial Neoplasms
1
Abiraterone Acetate
1
Interventions
Cyclophosphamide
82
Imatinib Mesylate
81
fludarabine phosphate
67
fludarabine
62
Whole-Body Irradiation
55
Mycophenolic Acid
54
Tacrolimus
42
nilotinib
40
Busulfan
39
Dasatinib
32
Cyclosporine
30
Peripheral Blood Stem Cell Transplantation
28
thymoglobulin
25
Melphalan
25
Thiotepa
24
Cytarabine
24
Granulocyte Colony-Stimulating Factor
23
Antilymphocyte Serum
23
Methotrexate
21
Filgrastim
21
Stem Cell Transplantation
20
ponatinib
16
Sirolimus
16
sargramostim
14
Cord Blood Stem Cell Transplantation
13
Rituximab
11
Cyclosporins
11
Clofarabine
11
venetoclax
10
peginterferon alfa-2b
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
×
BID protein, human
×
Clear all
NCT03906292
2025-03-10
CMLXI
University of Jena
Phase 2
Active not recruiting
125 enrolled